Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now early-phase tilt small index

Locally Advanced Hepatocellular Carcinoma: early-phase trial registry

3 of 4 indexed Locally Advanced Hepatocellular Carcinoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #4,115 of 28,707 conditions by registered trial count.

4 US clinical trials · 3 currently recruiting · #4,115 of 28,707 conditions by registered trial count

Locally Advanced Hepatocellular Carcinoma: 4 US clinical trials tracked, 3 recruiting.

Locally Advanced Hepatocellular Carcinoma is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Academic and Community Cancer Research United, running 1 of these trials.

Enrollment posture brief

Registry condition locally-advanced-hepatocellular-carcinoma

OPEN 3 | RECR 75% | LATE 0 | EARLY 4 | RANK #4115 | SPON 1

Nearest open-share peer: Activity, Motor (75% recruiting · 8 trials)

Ablation80%ACL Reconstruction80%Locally Advanced Hepatoc (th…75%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Locally Advanced Hepatocellular Carcinoma

Locally Advanced Hepatocellular Carcinoma lists 3 open slots (75% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Locally Advanced Hepatocellular Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Locally Advanced Hepatocellular Carcinoma is recruiting above its size-band peers.

    3 of 4 indexed trials (75%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 12Phase 22

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 2

Named interventions

Most-linked intervention names on Locally Advanced Hepatocellular Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Tremelimumab Biological
1 trials
Olanzapine Drug
1 trials
Lenvatinib Drug
1 trials
Placebo Administration Drug
1 trials
Cabozantinib Drug
1 trials
Questionnaire Administration Other
1 trials
Durvalumab Biological
1 trials
Atezolizumab Biological
1 trials

US sites by state

Facility locations filed on Locally Advanced Hepatocellular Carcinoma trials. A trial with sites in several states counts in each.

Wisconsin 1 trials
South Dakota 1 trials
Pennsylvania 1 trials
Oregon 1 trials
Ohio 1 trials
New York 1 trials
North Carolina 1 trials
Minnesota 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Locally Advanced Hepatocellular Carcinoma page

4 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Locally Advanced Hepatocellular Carcinoma condition card totals 4 registered trials; most-linked intervention Tremelimumab; top US site state Wisconsin. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.